EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In-vitro and In-vivo Assessment of Novel Sustained-release Local Drug Delivery Systems for Periodontal Therapy

Ketha Ramya, Vikas Singh, Pradeep Tangade, Ankita Jain, Prasanna K Gudali, Swayam S Tripathy

Journal of Pharmacy and Bioallied Sciences · 2026-01 · 18 (1) · 43-45

DOI: 10.4103/jpbs.jpbs_1767_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Bioallied Sciences, online erschienen am 12.03.2026. Verfasst von Ketha Ramya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Dentistry, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, Uttar Pradesh, India. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Local drug delivery (LDD) systems have gained prominence in periodontal therapy due to their ability to achieve high drug concentrations at diseased sites while minimizing systemic adverse effects. Sustained-release formulations may further enhance therapeutic efficacy by prolonging drug bioavailability within periodontal pockets.

Methods

This combined in-vitro – in-vivo experimental study evaluated a novel biodegradable sustained-release LDD system containing doxycycline hyclate. In-vitro analysis assessed drug release kinetics, antibacterial efficacy, and biocompatibility. In-vivo evaluation involved 60 patients with chronic periodontitis randomly allocated to three groups: Group I (scaling and root planing [SRP] + sustained-release doxycycline gel), Group II (SRP + conventional doxycycline gel), and Group III (SRP alone). Clinical parameters, including probing pocket depth (PPD), clinical attachment level (CAL), and gingival index (GI), were recorded at baseline, 1 month, and 3 months.

Results

In-vitro testing demonstrated sustained drug release up to 14 days with a cumulative release of 92.6 ± 3.1%. Group I showed significantly greater reductions in PPD (3.1 ± 0.6 mm) and CAL gain (2.8 ± 0.5 mm) at 3 months compared with Group II and Group III ( P < 0.001). Microbial reduction was highest in Group I (78.4%).

Conclusion

The novel sustained-release LDD system demonstrated superior in-vitro release characteristics and enhanced clinical outcomes when used as an adjunct to SRP, supporting its potential role in advanced periodontal therapy.

Schlagwörter

Stichwörter der Autor:innen

Doxycyclinelocal drug deliveryperiodontal therapyperiodontitissustained release

Autor:innen und Institutionen

  • Department of Public Health Dentistry, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, Uttar Pradesh, India.
  • Department of Periodontology and Implantology, Government Dental College and Hospital, Kadapa, Andhra Pradesh, India.

Zitieren

APA

Ramya, K., Singh, V., Tangade, P., Jain, A., Gudali, P. K., & Tripathy, S. S. (2026). In-vitro and In-vivo Assessment of Novel Sustained-release Local Drug Delivery Systems for Periodontal Therapy. Journal of Pharmacy and Bioallied Sciences, 18(1), 43-45. https://doi.org/10.4103/jpbs.jpbs_1767_25

Vancouver

Ramya K, Singh V, Tangade P, Jain A, Gudali PK, Tripathy SS. In-vitro and In-vivo Assessment of Novel Sustained-release Local Drug Delivery Systems for Periodontal Therapy. Journal of Pharmacy and Bioallied Sciences. 2026;18(1):43-45. doi:10.4103/jpbs.jpbs_1767_25

BibTeX
@article{Ramya2026,
  author = {Ramya, Ketha and Singh, Vikas and Tangade, Pradeep and Jain, Ankita and Gudali, Prasanna K and Tripathy, Swayam S},
  title = {In-vitro and In-vivo Assessment of Novel Sustained-release Local Drug Delivery Systems for Periodontal Therapy},
  journal = {Journal of Pharmacy and Bioallied Sciences},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {43--45},
  doi = {10.4103/jpbs.jpbs_1767_25}
}
Kostenlos starten →